NEXAVAR Drug Patent Profile

Which patents cover Nexavar, and when can generic versions of Nexavar launch?

Nexavar is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sorafenib tosylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexavar

A generic version of NEXAVAR was approved as sorafenib tosylate by MYLAN on September 10^th, 2020.

Summary for NEXAVAR

International Patents:	89
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	301
Patent Applications:	1,887
Drug Prices:	Drug price information for NEXAVAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXAVAR
What excipients (inactive ingredients) are in NEXAVAR?	NEXAVAR excipients list
DailyMed Link:	NEXAVAR at DailyMed

See drug prices for NEXAVAR

Recent Clinical Trials for NEXAVAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Disruptive Pharma	EARLY_PHASE1
CTC Clinical Trial Consultants AB	EARLY_PHASE1
Second Xiangya Hospital of Central South University	Phase 2/Phase 3

See all NEXAVAR clinical trials

Pharmacology for NEXAVAR

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for NEXAVAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXAVAR	Tablets	sorafenib tosylate	200 mg	021923	1	2014-02-28

US Patents and Regulatory Information for NEXAVAR

NEXAVAR is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005	AB	RX	Yes	Yes			Y	Y
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005	AB	RX	Yes	Yes			Y

Expired US Patents for NEXAVAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005
Bayer Hlthcare	NEXAVAR	sorafenib tosylate	TABLET;ORAL	021923-001	Dec 20, 2005

International Patents for NEXAVAR

See the table below for patents covering NEXAVAR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	035310	DIFENILUREAS SUBSTITUIDAS CON OMEGA CARBOXIARILO COMO INHIBIDORES DE RAF QUINASA; SUS COMPOSICIONES FARMACEUTICAS Y UN METODO PARA EL TRATAMIENTO DEL CRECIMIENTO DE CELULAS CANCEROSAS
Argentina	077485	DIFENILUREAS SUBSTITUIDAS CON CARBOXIARILO COMO INHIBIDORES DE RAF QUINASA
Austria	321027
Austria	460398
Austria	520663
Austria	538794

Supplementary Protection Certificates for NEXAVAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1140840	91280	Luxembourg		91280, EXPIRES: 20210720
1140840	PA2006008	Lithuania		PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840	300242	Netherlands
1140840	06C0034	France		PRODUCT NAME: SORAFENIB TOSYLATE, ET AUTRES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE SORAFENIB; REGISTRATION NO/DATE IN FRANCE: EU/1/06/342/001 DU 20060719; REGISTRATION NO/DATE AT EEC: EU/1/06/342/001 DU 20060719
1140840	CA 2007 00002	Denmark		PRODUCT NAME: SORAFENIB TOSYLAT
1140840	SPC 031/2006	Ireland		SPC 031/2006: 20070528, EXPIRES: 20210718

Nexavar (sorafenib) Market Dynamics and Financial Trajectory: Sales Trends, Pricing, Competition, and Patent/Regulatory Drivers

Last updated: July 21, 2026

Executive summary: Nexavar (sorafenib) has shifted from early high-growth oncology franchise status to a late-period, portfolio-stabilizing product with declining global sales under sustained price erosion, loss of exclusivity-driven competition in multiple markets, and treatment-line displacement by newer kinase inhibitors and immuno-oncology regimens. The financial trajectory is dominated by (1) geography-specific generic entry timelines and reimbursement dynamics, (2) class-level competition in RCC and HCC, and (3) incremental label pressure as clinicians move sorafenib earlier or later depending on guideline evolution. Any forward-looking forecast is constrained by the long tail of patent and formulation protection plus continuing biosimilar-like substitution behavior for small-molecule generics once market exclusivity ends.

How have Nexavar sales trended since launch and what is the current market size?

Direct answer: Nexavar is in a mature, declining-to-flat late lifecycle in most OECD markets, with residual volume supported by established clinical utility, slower uptake in some markets due to tendering and reimbursement structures, and ongoing use where newer agents are not accessible or not preferred.

What do the sales dynamics show in real terms?

Key drivers of the financial trajectory typically follow this pattern for mature oncology tyrosine kinase inhibitors:

• Initial peak and growth: Sorafenib’s early adoption in metastatic RCC and advanced HCC created high uptake through the late 2000s.
• Mid-lifecycle volatility: Competitive entrants changed sequencing (RCC) and regional HCC practice (immunotherapy combinations).
• Late decline: Generic erosion after exclusivity windows reduced pricing power; volume often falls because newer targeted agents and immunotherapies displace sorafenib in first-line or second-line settings.

How geography changes the “global” picture

Market size and revenue momentum depend heavily on:

• Generic entry timing by jurisdiction (US, EU member states, UK, major ex-US markets)
• Reimbursement status and guideline adherence
• Tender pricing and hospital formularies
• Portfolio strategy by Bayer and local distributors

What competitive drugs pressure Nexavar in RCC and HCC?

Direct answer: Nexavar faces sustained displacement pressure from newer kinase inhibitors and immunotherapy regimens in both RCC and HCC, which compress usable addressable population and lower payer willingness to reimburse expensive targeted therapies.

RCC: which classes reduced sorafenib’s addressable market?

Clinicians increasingly favor:

• VEGF/VEGFR inhibitors with stronger efficacy signals in practice
• Combination strategies (TKI plus PD-1/PD-L1)
• Mechanism-diverse regimens that improve response durability versus older TKI sequences

This reduces sorafenib share particularly where:

• It falls out of preferred first-line pathways.
• Second-line switching is dominated by agents with better tolerability or survival outcomes.

HCC: which regimens displaced sorafenib?

HCC practice has shifted with:

• Immuno-oncology combinations (PD-1/PD-L1 based)
• Multi-TKI sequencing driven by improved response rates and guideline updates

Sorafenib remains relevant where access to newer combinations is limited, but its revenue runway is shortened when payers adopt newer standard-of-care regimens.

When does Nexavar lose exclusivity and what does that imply for financial trajectory?

Direct answer: Nexavar’s exclusivity has largely ended; the financial trajectory after exclusivity is primarily a function of generic penetration, tender pricing, and residual branded premium in specific channels.

How exclusivity loss translates into revenue

Once exclusivity ends, revenue typically declines through:

• Price compression to generic benchmarks
• Formulary substitution
• Loss of prescriber preference except where patient continuity, safety perceptions, or procurement contracts delay switching

Patent-driven revenue versus generic-driven revenue

For late lifecycle small molecules, the limiting factor is less “patent estate strength” and more:

• Whether meaningful branded supply contracts persist
• Whether governments or payers move quickly to lowest-cost generics
• Whether Bayer retains any protected formulations, dosing, or packaging advantages in specific markets

What patents protect Nexavar and how strong is the patent estate?

Direct answer: Sorafenib’s patent estate is generally associated with early composition-of-matter and follow-on improvements (formulations, crystalline forms, manufacturing methods). For Nexavar’s finance impact, the commercial effect hinges on whether any non-expired follow-on patents remain in key geographies and whether they block generic entry or only shape design-around timelines.

Commercial relevance of follow-on patents

Even when composition-of-matter is expired, follow-on IP can affect:

• Switching speed (if a generic faces a non-infringement or licensing hurdle)
• Exclusivity wrappers in specific markets or for specific presentations
• Manufacturing process constraints that increase generic launch costs

Where patent strength matters most

• US: litigation and Paragraph IV pathways can delay generic launch.
• EU and major markets: litigation and local patent enforcement practices can slow substitution.

What is the Orange Book status of Nexavar and what does it mean for generic launches?

Direct answer: Nexavar (sorafenib) has an Orange Book listing history consistent with a mature small-molecule product, with generic entry enabled once relevant listed patents expire or are cleared via Paragraph IV litigation/settlement or through non-infringement determinations.

How Orange Book status affects launch timing

Generic outcomes typically fall into three buckets:

• No stay: immediate launch after patent expiration
• Paragraph IV litigation: potential 30-month stay with settlement or court decisions
• Settlement agreements: authorized launch dates that can create temporary generic protection for branded pricing

Have there been Paragraph IV challenges for Nexavar, and who filed them?

Direct answer: Nexavar’s class has historically attracted Paragraph IV filings for long-expired small-molecule patent portfolios, with litigation outcomes shaping launch timetables in the US.

How Paragraph IV affects financials

Even one delayed generic launch can:

• Sustain branded pricing for an additional period
• Reduce volume loss
• Preserve cashflow and enable portfolio reallocation

After multiple generic entries, the effect reverses: each additional generic increases competitive pricing and reduces branded net receipts.

What patent litigation affects Nexavar and how do settlements change the market?

Direct answer: In mature branded oncology TKIs, litigation and settlements mainly determine the pace of generic penetration, not the eventual end-state of generic substitution.

Financial implications of settlement structures

Settlements can influence:

• Authorized generic timing
• Geographic scope
• Product presentation scope
• Settlement payment and marketing restrictions that affect pharmacy channel behavior

What formulations are protected for Nexavar and do they affect pricing?

Direct answer: For small-molecule drugs, formulation or manufacturing patents can affect which generic products can enter cleanly and at what speed, but they rarely restore long-term branded pricing once broad generic availability exists.

Presentation-specific impacts

If a branded product retains:

• specific tablet/strength protections,
• unique coating or manufacturing method IP, generic manufacturers may delay or redesign launches. That can preserve a branded premium in narrow time windows or specific channels, usually not for the entire remaining lifecycle.

How does Nexavar’s financial trajectory compare with other marketed sorafenib strategies?

Direct answer: Nexavar’s financial trajectory is typical for a first-generation targeted oncology therapy: once displaced by newer regimens and subjected to generic substitution, branded revenues contract toward residual niche use rather than maintaining franchise growth.

Benchmarking against peers

In oncology, first-wave TKIs usually show:

• higher early adoption
• mid-term displacement when immuno-oncology and newer TKIs dominate guidelines
• late lifecycle stabilization only where branded-to-generic conversion is slower or patient continuity matters

Which companies compete with Nexavar in generics and what pricing pressure results?

Direct answer: Competitive pressure comes from multinational generics and local Indian, EU, and global manufacturers that supply sorafenib generics into major distribution channels, with pricing set by tender and volume dynamics rather than clinical differentiation.

What drives generic pricing pressure

• Multiple suppliers increase competition and reduce unit price.
• Tender-based procurement in hospitals pushes prices toward the lowest bid.
• Limited differentiated supply (no meaningful clinical differentiation) makes payer choice price-driven.

When could a generic or biosimilar-like disruption occur for Nexavar?

Direct answer: For small molecules like sorafenib, “biosimilar-like” disruption is not applicable. Market disruption occurs via:

• Generic entry waves
• Authorized generic launch events
• Settlement-driven timing changes
• Supply chain constraints that temporarily affect availability and pricing

What are the regulatory and labeling dynamics that influence uptake?

Direct answer: Uptake depends on labeling breadth, safety management requirements, and how guideline placement evolves. Sorafenib remains clinically established, but utilization declines when newer regimens are preferred in first-line or combination settings.

FDA and global regulatory pathways

For generics:

• ANDA approvals follow expiration/clearance of listed patents or Paragraph IV litigation outcomes. For branded:
• Label expansions and safety updates affect prescribing patterns, but they do not reverse macro-level generic substitution once competition is entrenched.

Key timeline of commercialization and lifecycle forces

Lifecycle forces table (market and financial impact)

Period	Market condition	Financial impact on Nexavar
Early branded growth	Limited competition, high adoption in RCC/HCC	Revenue growth and payer coverage expansion
Mid-lifecycle	Emerging competition and shifting sequencing	Revenue volatility; margin compression starts
Late lifecycle	Broad generic presence and guideline displacement	Persistent decline or flat-to-declining sales; residual niche demand
Ongoing maturity	Tender-driven pricing; multi-supplier competition	Low pricing power; cashflow stabilization only

Key Takeaways

• Nexavar’s financial trajectory is shaped less by incremental product innovation and more by exclusivity expiry, generic entry speed, and guideline-driven displacement in RCC and HCC.
• Competitive pressure from newer kinase inhibitors and immuno-oncology regimens reduces the addressable share even where sorafenib remains used.
• Late-stage branded revenues typically stabilize only in pockets where reimbursement and tendering delay generic substitution; otherwise they trend down with price erosion.
• Litigation and Orange Book dynamics primarily affect timing of generic erosion, not the eventual substitution end-state.

FAQs

1. How quickly do generic sorafenib products replace Nexavar after patent expiration in the US and EU?
2. Does sorafenib’s label breadth in RCC and HCC materially affect residual branded demand after generic entry?
3. What tends to drive the largest margin compression for mature oncology TKIs: price or volume?
4. How do hospital tendering practices influence the speed of substitution from branded Nexavar to generics?
5. Which competitive regimen shifts most directly reduce sorafenib use in first-line or second-line RCC?

References

1. FDA. Orange Book: Approved Drug Products (Drug Name: Nexavar; Active Ingredient: sorafenib). U.S. Food and Drug Administration.
2. FDA. ANDA/Litigation and Orange Book patent listings for approved sorafenib products. U.S. Food and Drug Administration.
3. NCCN Guidelines for Kidney Cancer and Hepatobiliary Cancers (versions reflecting guideline updates impacting sorafenib sequencing). National Comprehensive Cancer Network.

DrugChatter Q&A for NEXAVAR

Nexavar patent expiry date canada?
Nexavar blockbuster loss of exclusivity?
Does medicare cover nexavar?
Nexavar sorafenib us patent expiration date?
Can nexavar treat thyroid cancer?